Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2010

01.03.2010 | Original Article

Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer

verfasst von: Hervé Tixier, Jean Fraisse, Bruno Chauffert, Françoise Mayer, Sylvain Causeret, Catherine Loustalot, Coralie Deville, Franck Bonnetain, Paul Sagot, Serge Douvier, Jean Cuisenier

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The main aim of this study was to show the interest of pelvic posterior exenteration to obtain complete resection of the tumor in case of invasion of the rectum by contiguity in advanced-stage ovarian cancer. The secondary aim was to determine the morbidity of this surgery.

Methods

It is a multicentric, retrospective study of a series of 41 patients, who underwent posterior pelvectomy for advanced-stage ovarian cancer, over a period of 18 years, from July 1989 to July 2007.

Results

The surgery resulted in macroscopically complete resection in 19 patients (46.34%), a residual tumor <2 cm in 19 patients (46.34%) and >2 cm in 3 patients (7.32%). In 34 patients (34/41), digestive continuity with satisfactory anal sphincter function was restored immediately or in the short term. The mean delay to the start of complementary treatment was 36 days. Median overall survival was 33 months.

Conclusion

The main aim of surgery for ovarian peritoneal carcinomatosis is to obtain a complete resection. In the case of direct invasion of the rectum by contiguity, when there is no cleavage plane between the uterus and the rectum, pelvic posterior exenteration is an effective method to achieve this objective. Morbidity is relatively high, but acceptable given the poor prognosis of this disease, the improved survival after surgery, and improvements in post-operative quality of life and functions.
Literatur
1.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRefPubMed Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRefPubMed
2.
Zurück zum Zitat Du Bois A, Harter P (2006) The role of surgery in advanced and recurrent ovarian cancer. Ann Oncol 17(Suppl 10):x235–x240CrossRefPubMed Du Bois A, Harter P (2006) The role of surgery in advanced and recurrent ovarian cancer. Ann Oncol 17(Suppl 10):x235–x240CrossRefPubMed
3.
Zurück zum Zitat Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69(2):103–108CrossRefPubMed Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69(2):103–108CrossRefPubMed
4.
Zurück zum Zitat Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed
5.
Zurück zum Zitat Griffiths CT, Parker LM, Fuller AF Jr (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63(2):235–240PubMed Griffiths CT, Parker LM, Fuller AF Jr (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63(2):235–240PubMed
6.
Zurück zum Zitat Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61(4):413–420PubMed Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61(4):413–420PubMed
7.
Zurück zum Zitat Skirnisdottir I, Sorbe B (2007) Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III–IV) epithelial ovarian carcinoma. Int J Oncol 30(3):727–734PubMed Skirnisdottir I, Sorbe B (2007) Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III–IV) epithelial ovarian carcinoma. Int J Oncol 30(3):727–734PubMed
8.
Zurück zum Zitat Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois BA (2007) Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106(1):69–74CrossRefPubMed Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois BA (2007) Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106(1):69–74CrossRefPubMed
9.
Zurück zum Zitat Scholz HS, Tasdemir H, Hunlich T, Turnwald W, Both A, Egger H (2007) Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol 106(3):591–595CrossRefPubMed Scholz HS, Tasdemir H, Hunlich T, Turnwald W, Both A, Egger H (2007) Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol 106(3):591–595CrossRefPubMed
10.
Zurück zum Zitat Du Bois BA, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244CrossRefPubMed Du Bois BA, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244CrossRefPubMed
11.
Zurück zum Zitat Pomel C, Barton DP, McNeish I, Shepherd J (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG 115(7):808–810CrossRefPubMed Pomel C, Barton DP, McNeish I, Shepherd J (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG 115(7):808–810CrossRefPubMed
12.
Zurück zum Zitat Carmignani CP, Sugarbaker PH (2004) Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience. Expert Rev Anticancer Ther 4(3):477–487CrossRefPubMed Carmignani CP, Sugarbaker PH (2004) Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience. Expert Rev Anticancer Ther 4(3):477–487CrossRefPubMed
13.
Zurück zum Zitat Sugarbaker PH (1996) Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res 81:75–87PubMed Sugarbaker PH (1996) Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res 81:75–87PubMed
14.
Zurück zum Zitat Hudson CN, Dendy PP (1974) Aspects of treatment of more advanced cases of ovarian cancer. Proc R Soc Med 67(8):798–801PubMed Hudson CN, Dendy PP (1974) Aspects of treatment of more advanced cases of ovarian cancer. Proc R Soc Med 67(8):798–801PubMed
15.
Zurück zum Zitat Hudson CN (1978) The place of surgery in the treatment of ovarian cancer. Clin Obstet Gynaecol 5(3):695–708PubMed Hudson CN (1978) The place of surgery in the treatment of ovarian cancer. Clin Obstet Gynaecol 5(3):695–708PubMed
16.
Zurück zum Zitat Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23(34):8802–8811CrossRefPubMed Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23(34):8802–8811CrossRefPubMed
17.
Zurück zum Zitat Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM et al (2007) Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 43(1):149–160CrossRefPubMed Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM et al (2007) Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 43(1):149–160CrossRefPubMed
18.
Zurück zum Zitat Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H et al (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5):v128–v149CrossRefPubMed Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H et al (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5):v128–v149CrossRefPubMed
19.
Zurück zum Zitat Colonna M, Hedelin G, Esteve J, Grosclaude P, Launoy G, Buemi A et al (2000) National cancer prevalence estimation in France. Int J Cancer 87(2):301–304CrossRefPubMed Colonna M, Hedelin G, Esteve J, Grosclaude P, Launoy G, Buemi A et al (2000) National cancer prevalence estimation in France. Int J Cancer 87(2):301–304CrossRefPubMed
20.
Zurück zum Zitat Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F et al (2003) Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 51(1 Pt 1):3–30PubMed Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F et al (2003) Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 51(1 Pt 1):3–30PubMed
21.
Zurück zum Zitat Tretarre B, Remontet L, Menegoz F, Mace-Lesec’h J, Grosclaude P, Buemi A et al (2005) Ovarian cancer: incidence and mortality in France. J Gynecol Obstet Biol Reprod (Paris) 34(2):154–161 Tretarre B, Remontet L, Menegoz F, Mace-Lesec’h J, Grosclaude P, Buemi A et al (2005) Ovarian cancer: incidence and mortality in France. J Gynecol Obstet Biol Reprod (Paris) 34(2):154–161
22.
Zurück zum Zitat Bridges J, Oram D (1993) Management of advanced gynaecological malignancies. Br J Hosp Med 49(3):191–199PubMed Bridges J, Oram D (1993) Management of advanced gynaecological malignancies. Br J Hosp Med 49(3):191–199PubMed
23.
Zurück zum Zitat Buttarelli M, Houvenaeghel G, Lelievre L, Jacquemier J, Guiramand J, Delpero JR (2006) Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma? Ann Chir 131(8):431–436CrossRefPubMed Buttarelli M, Houvenaeghel G, Lelievre L, Jacquemier J, Guiramand J, Delpero JR (2006) Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma? Ann Chir 131(8):431–436CrossRefPubMed
24.
Zurück zum Zitat Eisenkop SM, Nalick RH, Teng NN (1991) Modified posterior exenteration for ovarian cancer. Obstet Gynecol 78(5 Pt 1):879–885PubMed Eisenkop SM, Nalick RH, Teng NN (1991) Modified posterior exenteration for ovarian cancer. Obstet Gynecol 78(5 Pt 1):879–885PubMed
25.
Zurück zum Zitat Soper JT, Couchman G, Berchuck A, Clarke-Pearson D (1991) The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol 41(3):239–244CrossRefPubMed Soper JT, Couchman G, Berchuck A, Clarke-Pearson D (1991) The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol 41(3):239–244CrossRefPubMed
26.
Zurück zum Zitat Mourton SM, Temple LK, bu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH et al (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614CrossRefPubMed Mourton SM, Temple LK, bu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH et al (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614CrossRefPubMed
27.
Zurück zum Zitat Mirhashemi R, Averette HE, Estape R, Angioli R, Mahran R, Mendez L et al (2000) Low colorectal anastomosis after radical pelvic surgery: a risk factor analysis. Am J Obstet Gynecol 183(6):1375–1379CrossRefPubMed Mirhashemi R, Averette HE, Estape R, Angioli R, Mahran R, Mendez L et al (2000) Low colorectal anastomosis after radical pelvic surgery: a risk factor analysis. Am J Obstet Gynecol 183(6):1375–1379CrossRefPubMed
28.
Zurück zum Zitat Blythe JG, Wahl TP (1982) Debulking surgery: does it increase the quality of survival? Gynecol Oncol 14(3):396–408CrossRefPubMed Blythe JG, Wahl TP (1982) Debulking surgery: does it increase the quality of survival? Gynecol Oncol 14(3):396–408CrossRefPubMed
29.
Zurück zum Zitat Spirtos NM, Eisenkop SM, Schlaerth JB, Ballon SC (2000) Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer. Am J Obstet Gynecol 182(6):1321–1327CrossRefPubMed Spirtos NM, Eisenkop SM, Schlaerth JB, Ballon SC (2000) Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer. Am J Obstet Gynecol 182(6):1321–1327CrossRefPubMed
Metadaten
Titel
Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer
verfasst von
Hervé Tixier
Jean Fraisse
Bruno Chauffert
Françoise Mayer
Sylvain Causeret
Catherine Loustalot
Coralie Deville
Franck Bonnetain
Paul Sagot
Serge Douvier
Jean Cuisenier
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2010
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-009-1175-0

Weitere Artikel der Ausgabe 3/2010

Archives of Gynecology and Obstetrics 3/2010 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.